—
C+
C+ The full Closelook — membership. Open the C+ overview

Arrowhead Pharmaceuticals Inc (ARWR) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Arrowhead Pharmaceuticals Inc

ARWR in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline. It is based in Pasadena, California.
Where it sits in the stack
Arrowhead carries no seat in our indices; it sits in the Healthcare sector of Closelook's US universe, grouped with clinical-stage biotechnology names developing RNA interference therapeutics for chronic disease, rather than in any AI infrastructure sleeve.
Who it is priced against
The peer group draws on other scored healthcare names based in the US, including Regeneron, Vertex and BeiGene; the market also compares Arrowhead with Alnylam Pharmaceuticals as another RNA interference developer.
Why Closelook tracks it
Arrowhead carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in its editions.
What the diary watches
The diary watches whether pipeline candidates advance through their trial phases and whether partner collaborations expand, since either would alter the read on the shares.

Arrowhead Pharmaceuticals Inc (ARWR) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 47/100 composite (momentum 53, quality 34, valuation 11) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ARWR, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ARWR on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ARWR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +11.7% in FY2025 63 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Arrowhead Pharmaceuticals Inc (ARWR)?

Arrowhead Pharmaceuticals Inc trades as ARWR on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is ARWR in a Closelook index?

Not currently — Arrowhead Pharmaceuticals Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Arrowhead Pharmaceuticals Inc's Closelook composite score?

47 out of 100, with momentum 53, quality 34 and valuation 11 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ARWR trade against its moving averages?

Mixed moving-average stack: Trades -12.9% vs the 50-day and -1% vs the 200-day average, 24.7% below the 52-week high and +134% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Arrowhead Pharmaceuticals Inc do?

Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline. It is based in Pasadena, California. The peer group draws on other scored healthcare names based in the US, including Regeneron, Vertex and BeiGene; the market also compares Arrowhead with Alnylam Pharmaceuticals as another RNA interference developer.

Where does Arrowhead Pharmaceuticals Inc sit in the AI build-out?

Arrowhead carries no seat in our indices; it sits in the Healthcare sector of Closelook's US universe, grouped with clinical-stage biotechnology names developing RNA interference therapeutics for chronic disease, rather than in any AI infrastructure sleeve. Arrowhead carries a Closelook score, with momentum the strongest module and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in its editions.

Does Arrowhead Pharmaceuticals Inc pay a dividend?

No cash distribution shows in Arrowhead Pharmaceuticals Inc’s price series over the last three years. The share count rose 11.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARWR, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.